{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.2","value":"-16.9"}]}],"title":"Physical Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.4","value":"-7.8"}]}],"title":"Role Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.5","value":"-13.9"}]}],"title":"Emotional Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.7","value":"-4.4"}]}],"title":"Cognitive Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.8","value":"-12.2"}]}],"title":"Social Functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.0","value":"11.9"}]}],"title":"Fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.8","value":"-3.3"}]}],"title":"Pain"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.8","value":"10.0"}]}],"title":"Nausea and Vomiting"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.5","value":"-9.4"}]}],"title":"Global Health Status"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.7","value":"8.9"}]}],"title":"Dyspnoea"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.3","value":"13.3"}]}],"title":"Appetite Loss"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.9","value":"-11.1"}]}],"title":"Insomnia"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.4","value":"-4.4"}]}],"title":"Constipation"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.8","value":"-2.2"}]}],"title":"Diarrhoea"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.0","value":"6.7"}]}],"title":"Financial Difficulties"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"description":"EORTC QLQ-C30 was administered on day 1 of each treatment cycle. EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Insomnia, Appetite Loss, Constipation, Diarrhea, Financial Impact).\n\nFor each of these scales, scores range from 0 to 100. For the GHS and 5 functional scales a high score indicates better global health status/functioning and a positive change from baseline indicates improvement. For the 9 symptom scales, a high score indicates a higher level of symptoms, and a negative change from Baseline indicates an improvement in symptoms.\n\nChange from baseline is the difference in the average score from cycles 2 to 6 and the score on cycle 1 day 1.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received carfilzomib administered as an intravenous (IV) infusion twice-weekly for up to six 28-day cycles followed by once-weekly for another six 28-day cycles. The carfilzomib dose was 20 mg/m² on days 1 and 2 of cycle 1, 56 mg/m² for the remaining days of cycle 1 (days 8, 9, 15, and 16) and then on days 1, 2, 8, 9, 15, and 16 of each cycle for cycles 2 to 6, and 70 mg/m² on days 1, 8, and 15 of each cycle for cycles 7 to 12.\n\nParticipants also received dexamethasone either orally or by IV infusion at a dose of 20 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 of cycles 1 to 6 and at a dose 40 mg once daily on days 1, 8, 15 of cycles 7 to 12.","id":"OG000","title":"Carfilzomib Plus Dexamethasone"}],"paramType":"MEAN","populationDescription":"Enrolled participants who completed 12 cycles of treatment","reportingStatus":"POSTED","timeFrame":"Baseline (cycle 1 day 1) and cycles 2 - 6","title":"Change From Baseline in Average EORTC QLQ-C30 Scores During Cycles 2 to 6 in Participants Who Completed 12 Cycles of Treatment","type":"SECONDARY","unitOfMeasure":"scores on a scale"}